Gillman J, et al. PET Clin 2020 - Review.
Although fluorodeoxyglucose PET/MR imaging is a promising new modality, there is not yet enough data to support its routine use for staging or surveillance of children with lymphoma. PET/MR imaging protocols are still under development, and its availability globally is limited. The cost-benefit of using PET/MR imaging has not yet been established, especially because annual post-treatment surveillance imaging with fluorodeoxyglucose PET is not necessary in most patients with lymphoma. Further
research into the use of PET/MR imaging in pediatric oncology patients is needed with continued collaborations among institutions.